Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia

被引:0
|
作者
Roman Hornung
Vindi Jurinovic
Aarif M. N. Batcha
Stefanos A. Bamopoulos
Maja Rothenberg-Thurley
Susanne Amler
Maria Cristina Sauerland
Wolfgang E. Berdel
Bernhard J. Wörmann
Stefan K. Bohlander
Jan Braess
Wolfgang Hiddemann
Sören Lehmann
Sylvain Mareschal
Karsten Spiekermann
Klaus H. Metzeler
Tobias Herold
Anne-Laure Boulesteix
机构
[1] Biometry and Epidemiology,Institute for Medical Information Processing
[2] LMU Munich,Department of Medicine III
[3] German Cancer Consortium (DKTK),Institute of Biostatistics and Clinical Research
[4] partner site Munich,Department of Medicine A, Hematology and Oncology
[5] German Cancer Research Center (DKFZ),Department of Molecular Medicine and Pathology
[6] University Hospital,Department of Oncology and Hematology
[7] LMU Munich,Department of Medical Sciences
[8] University of Muenster,Department of Medicine
[9] University of Muenster,Department of Biosciences and Nutrition
[10] German Society of Hematology and Oncology,undefined
[11] University of Auckland,undefined
[12] Hospital Barmherzige Brüder,undefined
[13] Uppsala University Hospital,undefined
[14] Karolinska Institute,undefined
[15] Karolinska Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Alterations of RUNX1 in acute myeloid leukemia (AML) are associated with either a more favorable outcome in the case of the RUNX1/RUNX1T1 fusion or unfavorable prognosis in the case of point mutations. In this project we aimed to identify genes responsible for the observed differences in outcome that are common to both RUNX1 alterations. Analyzing four AML gene expression data sets (n = 1514), a total of 80 patients with RUNX1/RUNX1T1 and 156 patients with point mutations in RUNX1 were compared. Using the statistical tool of mediation analysis we identified the genes CD109, HOPX, and KIAA0125 as candidates for mediator genes. In an analysis of an independent validation cohort, KIAA0125 again showed a significant influence with respect to the impact of the RUNX1/RUNX1T1 fusion. While there were no significant results for the other two genes in this smaller validation cohort, the observed relations linked with mediation effects (i.e., those between alterations, gene expression and survival) were almost without exception as strong as in the main analysis. Our analysis demonstrates that mediation analysis is a powerful tool in the identification of regulative networks in AML subgroups and could be further used to characterize the influence of genetic alterations.
引用
收藏
相关论文
共 50 条
  • [21] Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia
    Motomi Osato
    Oncogene, 2004, 23 : 4284 - 4296
  • [22] RUNX1::RUNX1T1 Impairs the Differentiation Potential of Primary AML Cells
    Derevianko, Polina K.
    Swart, Laura E.
    Ashtiani, Minoo
    Kellaway, Sophie
    Krippner-Heidenreich, Anja
    Schiffelers, Raymond M.
    Vormoor, Josef
    Heidenreich, Olaf
    BLOOD, 2023, 142
  • [23] RUNX1 Mutations Reduce the Expression of CEBPA in Acute Myeloid Leukemia
    Grossmann, Vera
    Kohlmann, Alexander
    Dicker, Frank
    Butschalowski, Katrin
    Kern, Wolfgang
    Schnittger, Susanne
    Haferlach, Torsten
    Haferlach, Claudia
    BLOOD, 2011, 118 (21) : 1040 - 1040
  • [24] RUNX1::RUNX1T1 Acute Myeloid Leukemia Cytogenetically Showing t(6;8)(p23;q22)
    Higuchi, Ai
    Iriyama, Noriyoshi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [25] AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR
    Yang, Xinhong
    Wu, Yingwei
    Yang, Xiaofeng
    Wu, Xue
    Chen, Yingying
    Zhang, Rongjuan
    Zhang, Zhihua
    CLINICAL LABORATORY, 2024, 70 (03) : 619 - 621
  • [26] INCIDENCE AND PROGNOSTIC IMPACT OF FLT3 AND NPM1 MUTATIONS IN ACUTE MYELOID LEUKEMIA AND CKIT AND NRAS GENE MUTATIONS IN RUNX1/RUNX1T1 AML
    Petrova, E.
    Martynkevich, I.
    Polushkina, L.
    Martynenko, L.
    Ivanova, M.
    Cybakova, N.
    Kleina, E.
    Shabanova, E.
    Gritsaev, S.
    Abdulkadyrov, K.
    HAEMATOLOGICA, 2014, 99 : 30 - 30
  • [27] A role for RUNX1 in hematopoiesis and myeloid leukemia
    Ichikawa, Motoshi
    Yoshimi, Akihide
    Nakagawa, Masahiro
    Nishimoto, Nahoko
    Watanabe-Okochi, Naoko
    Kurokawa, Mineo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) : 726 - 734
  • [28] Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
    Wang, Miao
    Cao, Han-Yu
    Tan, Kai-Wen
    Qiu, Qiao-Cheng
    Huang, Yuan-Hong
    Ge, Shuai-shuai
    Wang, Zi-Hao
    Chen, Jia
    Tang, Xiao-Wen
    Wu, De-Pei
    Xue, Sheng-Li
    Li, Zheng
    Dai, Hai-Ping
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [29] A role for RUNX1 in hematopoiesis and myeloid leukemia
    Motoshi Ichikawa
    Akihide Yoshimi
    Masahiro Nakagawa
    Nahoko Nishimoto
    Naoko Watanabe-Okochi
    Mineo Kurokawa
    International Journal of Hematology, 2013, 97 : 726 - 734
  • [30] Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
    Miao Wang
    Han-Yu Cao
    Kai-Wen Tan
    Qiao-Cheng Qiu
    Yuan-Hong Huang
    Shuai-shuai Ge
    Zi-Hao Wang
    Jia Chen
    Xiao-Wen Tang
    De-Pei Wu
    Sheng-Li Xue
    Zheng Li
    Hai-Ping Dai
    Blood Cancer Journal, 13